Profil bibliographique

Salaheldin S. Hamed

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

57Publications signalées

920Citations signalées

0Affiliations récentes

Les domaines associés

Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and BiomarkersProstate Cancer Treatment and ResearchPARP inhibition in cancer therapyMultiple and Secondary Primary Cancers

Les publications récentes

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Data 1 from Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9

Paul Swiecicki, Glenn J. Hanna, J.L. Geiger, Takao Fujisawa et autres

0 citations

Accès ouvert 2026 other OpenAlex

Table 4 from Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9

Paul Swiecicki, Glenn J. Hanna, J.L. Geiger, Takao Fujisawa et autres

0 citations

Accès ouvert 2026 other OpenAlex

Table 3 from Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9

Paul Swiecicki, Glenn J. Hanna, J.L. Geiger, Takao Fujisawa et autres

0 citations

Accès ouvert 2026 other OpenAlex

Data from Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9

Paul Swiecicki, Glenn J. Hanna, J.L. Geiger, Takao Fujisawa et autres

0 citations

Accès ouvert 2026 other OpenAlex

Figure 1 from Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9

Paul Swiecicki, Glenn J. Hanna, J.L. Geiger, Takao Fujisawa et autres

0 citations

Accès ouvert 2026 other OpenAlex

Table 1 from Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9

Paul Swiecicki, Glenn J. Hanna, J.L. Geiger, Takao Fujisawa et autres

0 citations

Accès ouvert 2026 other OpenAlex

Table 2 from Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9

Paul Swiecicki, Glenn J. Hanna, J.L. Geiger, Takao Fujisawa et autres

0 citations

Accès ouvert 2026 other OpenAlex

Figure 2 from Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9

Paul Swiecicki, Glenn J. Hanna, J.L. Geiger, Takao Fujisawa et autres

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Table S3 from FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma

William F. Maguire, Daniel Lee, Chana Weinstock, Xin Gao et autres

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Table S4 from FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma

William F. Maguire, Daniel Lee, Chana Weinstock, Xin Gao et autres

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Figure S1 from FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma

William F. Maguire, Daniel Lee, Chana Weinstock, Xin Gao et autres

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Table S2 from FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma

William F. Maguire, Daniel Lee, Chana Weinstock, Xin Gao et autres

0 citations

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.